Role of statins in the treatment of multiple sclerosis

Pharmacological Research

Volumn 87, Issue , 2014, Pages 133-143

  Ciurleo, Rosella ^a   Bramanti, Placido ^a   Marino, Silvia ^a,b  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Combination therapy; Immunomodulatory effect; Multiple sclerosis; Neuroprotection; Randomized clinical trial; Statins

Indexed keywords

ATORVASTATIN; B7 ANTIGEN; BETA INTERFERON; BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CD40 ANTIGEN; CD86 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON BETA SERINE; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; STAT4 PROTEIN; STAT6 PROTEIN; TRANSCRIPTION FACTOR T BET; VASCULAR CELL ADHESION MOLECULE 1; IMMUNOLOGIC FACTOR; NEUROPROTECTIVE AGENT; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 4; MATRIX METALLOPROTEINASE; PITAVASTATIN; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; STAT1 PROTEIN; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NEUROPROTECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STRUCTURE ANALYSIS; T LYMPHOCYTE ACTIVATION; ANIMAL; IMMUNOLOGY; TREATMENT OUTCOME; CELL ADHESION; CELL MIGRATION; CLINICAL EFFECTIVENESS; DOWN REGULATION; DRUG DETERMINATION; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME SYNTHESIS; HYPERLIPIDEMIA; IMMUNOPATHOGENESIS; LOW DRUG DOSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 84907598207     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.03.004     Document Type: Review

References (83)

1. J.L. Goldstein, and M.S. Brown Regulation of the mevalonate pathway Nature 343 6257 1990 425 430 10.1038/343425a0
2. A.M. Gotto Jr., and J.E. Moon Recent clinical studies of the effects of lipid-modifying therapies Am J Cardiol 110 1 2012 15A 26A 10.1016/j.amjcard. 2012.04.003
3. C.M. Minder, R.S. Blumenthal, and M.J. Blaha Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks Curr Opin Cardiol 28 5 2013 554 560 10.1097/HCO.0b013e32836429e6
4. F.L. Zhang, and P.J. Casey Protein prenylation: molecular mechanisms and functional consequences Annu Rev Biochem 65 1996 241 269 10.1146/annurev.bi.65. 070196.001325
5. J.H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B.G. Weinshenker Multiple sclerosis N Engl J Med 343 13 2000 938 952 10.1056/NEJM200009283431307
6. R. Ciurleo, P. Bramanti, L. Spadaro, and S. Marino Multiple sclerosis: drugs in advanced clinical development F.R.S. Atta-ur-Rahman, Frontiers in Clinical Drug Research - CNS and Neurological Disorders vol. 2 2013 Bentham Science Publisher Sharjah U.A.E. 181 297
7. B. Nikbin, M.M. Bonab, F. Khosravi, and F. Talebian Role of B cells in pathogenesis of multiple sclerosis Int Rev Neurobiol 79 2007 13 42 10.1016/S0074-7742(07)79002-5
8. R. Gold, C. Linington, and H. Lassmann Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research Brain 129 8 2006 1953 1971 10.1093/brain/awl075
9. R.M. Steinman, and J. Banchereau Taking dendritic cells into medicine Nature 449 7161 2007 419 426 10.1038/nature06175
10. Y. Yang, and M. Wilson CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling and T cell activation through CD40 Nature 273 1996 1863 1864 10.1126/science.273.5283.1862
11. B. Serani, B. Rosicarelli, R. Magliozzi, E. Stigliano, E. Capello, and G.L. Mancardi et al. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells J Neuropathol Exp Neurol 65 2 2006 124 141 10.1097/01.jnen.0000199572.96472.1c
12. A.L. Zozulya, B.D. Clarkson, S. Ortler, Z. Fabry, and H. Wiendl The role of dendritic cells in CNS autoimmunity J Mol Med 88 6 2010 535 544 10.1007/s00109-010-0607-4
13. M. Comabella, and S.J. Khoury Immunopathogenesis of multiple sclerosis Clin Immunol 142 1 2012 2 8 10.1016/j.clim.2011.03.004
14. S. Boppana, H. Huang, K. Ito, and S. Dhib-Jalbut Immunologic aspects of multiple sclerosis Mt Sinai J Med 78 2 2011 207 220 10.1002/msj.20249
15. E.M. Frohman, M.K. Racke, and C.S. Raine Multiple Sclerosis - the plaques and its pathogenesis N Engl J Med 354 9 2006 942 955 10.1056/NEJMra052130
16. V.I. Leussink, U.K. Zettl, S. Jander, R.B. Pepinsky, R.R. Lobb, and G. Stoll et al. Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis Acta Neuropathol 103 2 2002 131 136 10.1007/s004010100444
17. H. Kebir, I. Ifergan, J.I. Alvarez, M. Bernard, J. Poirier, and N. Arbour et al. Preferential recruitment of interferon-gamma expressing TH17 cells in multiple sclerosis Ann Neurol 66 3 2009 390 402 10.1002/ana.21748
18. B. Kwak, S. Mulhaupt, S. Myit, and F. Mach Statins as a newly recognized type of immunomodulator Nat Med 6 12 2000 1399 1402 10.1038/82219
19. S. Youssef, O. Stuve, J.C. Patarroyo, P.J. Ruiz, J.L. Radosevich, and E.M. Hur et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease Nature 420 6911 2002 78 84 10.1038/nature01158
20. X. Peng, J. Jin, S. Giri, M. Montes, D. Sujkowski, and Y. Tang et al. Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis J Neuroimmunol 178 1-2 2006 130 139 10.1016/j/jneuroim.2006.06.005
21. E. Zeinstra, N. Wilczak, D. Chesik, L. Glazenburg, F.G. Kroese, and J. De Keyser Simvastatin inhibits interferon-γ-induced MHC class II up-regulation in cultured astrocytes J Neuroinflamm 3 2006 6 10.1186/1742-2094-3-16
22. S. Lawman, C. Maur, E.C. Jury, H.T. Cook, and M.R. Eherenstein Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice J Immunol 173 12 2004 7641 7646
23. H.F. Kuipers, P.J. Biesta, T.A. Groothuis, J.J. Neefjes, A.M. Mommaas, and P.J. Van den Elsen Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol- containing microdomains Hum Immunol 66 6 2005 653 665 10.1016/j.humimm.2005.04. 004
24. A. Yilmaz, C. Reiss, O. Tantawi, A. Weng, C. Stumpf, and D. Raaz et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis Atherosclerosis 172 1 2004 85 93 10.1016/j.atherosclerosis.2003.10.002
25. A. Yilmaz, C. Reiss, A. Weng, I. Cicha, C. Stumpf, and A. Steinkasserer et al. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells J Leukoc Biol 79 3 2006 529 538 10.1189/jlb.0205064
26. X. Zhang, Y. Tao, J. Wang, R. Garcia-Mata, and S. Markovic-Plese Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis Eur J Immunol 43 1 2013 281 289 10.1002/eji.201242566
27. H. Bartosik-Psujek, J. Tabarkiewicz, K. Pocinska, S. Radej, Z. Stelmasiak, and J. Rolinski Immunomodulatory effects of IFN-β and lovastatin on immunophenotype of monocyte-derived dendritic cells in multiple sclerosis Arch Immunol Ther Exp 58 4 2010 313 319 10.1007/s00005-010-0084-z
28. N. Nath, S. Giri, R. Prasad, A.K. Singh, and I. Singh Potential targets 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy J Immunol 172 2 2004 1273 1286
29. S.E. Dunn, S. Youssef, M.J. Goldstein, T. Prod'homme, M.S. Weber, and S.S. Zamvil et al. Isoprenoid determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin J Exp Med 203 2 2006 401 412 10.1084/jem.20051129
30. R. Hakamada-Taguchi, Y. Uehara, K. Kuribayashi, A. Numabe, K. Saito, and H. Negoro et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development promotes Th2 development Circ Res 93 10 2003 948 956 10.1161/01.RE.S.0000101298.76864.14
31. H. Kohno, T. Sakai, S. Saito, K. Okano, and K. Kitahara Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin Exp Eye Res 84 3 2007 569 576 10.1016/j.exer.2006.11.011
32. M.E. Gegg, R. Harry, D. Hankey, H. Zambarakji, G. Pryce, and D. Baker et al. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction J Immunol 174 4 2005 2327 2335
33. M. Gambuzza, N. Licata, E. Palella, D. Celi, V. Foti Cuzzola, and D. Italiano et al. Targeting toll-like receptor: emerging therapeutics for multiple sclerosis management J Neuroimmunol 239 1-2 2011 1 12 10.1016/j.jneuroim.2011. 08.010
34. C. Van Der Putten, H.F. Kuipers, E.A. Zuiderwijk-Sick, L. Van Straalen, P.J. Van Den Elsen, and I. Kondova et al. Statins amplify TLR-induced responses in microglia via inhibition of cholesterol biosynthesis Glia 60 1 2012 43 52 10.1002/glia.21245
35. M. Matsumoto, D. Einhaus, E.S. Gold, and A. Aderem Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors J Immunol 172 12 2004 7377 7384
36. G.W. Konat, A. Krasowska-Zoladek, and M. Kraszpulski Statins enhance Toll-like receptor 4-mediated cytokine gene expression in astrocytes: implication of Rho proteins in negative feedback regulation J Neurosci Res 86 3 2008 603 609 10.1002/jnr.21509
37. + T cells derived from patients with multiple sclerosis J Immunol 187 6 2011 3431 3437 10.4049/jimmunol.1100580
38. + lymphocytes J Immunol 180 10 2008 6988 6996
39. V.S. Ramgolam, and S. Markovic-Plese Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis J Signal Transduct 2011 2011 635721 10.1155/2011/635721
40. D. Jo, D. Liu, S. Yao, R.D. Collins, and J. Hawiger Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis Nat Med 11 8 2005 892 898 10.1038/nm1269
41. G. Weitz-Schmidt, K. Welzenbach, V. Brinkmann, T. Kamata, J. Kallen, and C. Bruns et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site Nat Med 7 6 2001 687 692 10.1038/89058
42. C. Weber, W. Erl, K.S. Weber, and P.C. Weber HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes isolated from patients with hypercholesterolemia J Am Coll Cardiol 30 5 1997 1212 1217 10.1016/S0735-1097(97)00324-0
43. H.K. Chung, I.K. Lee, H. Kang, J.M. Suh, H. Kim, and K.C. Park et al. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells Exp Mol Med 34 6 2002 451 461 10.1038/emm.2002.63
44. Y.C. Doo, S.J. Han, S.W. Han, W.J. Park, S.H. Choi, and G.Y. Cho et al. Effect of preexisting statin use on expression of C-reactive protein, adhesion molecules, interleukin-6, and antioxidized low-density lipoprotein antibody in patients with unstable angina undergoing coronary stenting Clin Cardiol 28 2 2005 72 76
45. R. Prasad, S. Giri, N. Nath, I. Singh, and A.K. Singh Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction J Neurochem 94 1 2005 204 214 10.1111/j.1471-4159.2005.03182.x
46. B. Wong, W.C. Lumma, A.M. Smith, J.T. Sisko, S.D. Wright, and T.Q. Cai Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation J Leukoc Biol 69 6 2001 959 962
47. F. Ganne, M. Vasse, J.L. Beaudeux, J. Peynet, A. Francois, and Z. Mishal et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis Thromb Haemost 84 4 2000 680 688
48. B.D. Trapp, J. Peterson, R.M. Ransohoff, R. Rudick, S. Mörk, and L. Bö Axonal transection in the lesions of multiple sclerosis N Engl J Med 338 5 1998 278 285 10.1056/NEJM199801293380502
49. M.S. Windrem, N.S. Roy, J. Wang, M. Nunes, A. Benraiss, and R. Goodman et al. Progenitor cells derived from the adult human subcortical white matter disperse and differentiate as oligodendrocytes within demyelinated lesions of the art brain J Neurosci Res 69 6 2002 966 975 10.1002/jnr.10397
50. A.S. Paintlia, M.K. Paintlia, M. Khan, T. Vollmer, A.K. Singh, and I. Singh HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocytes progenitors in animal model of multiple sclerosis FASEB J 19 11 2005 1407 1421 10.1096/fj.05-3861com
51. A.S. Paintlia, M.K. Paintlia, A.K. Singh, and I. Singh Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis Mol Pharmacol 73 5 2008 1381 1393 10.1124/mol.107.044230
52. V.E. Miron, S. Rajasekharan, A.A. Jarjour, S.S. Zamvil, T.E. Kennedy, and J.P. Antel Simvastatin regulates oligodendroglial process dynamics and survival Glia 55 2 2007 130 143 10.1002/glia.20441
53. F.J. Sim, J.K. Lang, T.A. Ali, N.S. Roy, G.E. Vates, and W.H. Pilcher et al. Statin treatment of adult human glial progenitors induces PPAR gamma-mediated oligodendrocytic differentiation Glia 56 9 2008 954 962 10.1002/glia.20669
54. S. Klopfleisch, D. Merkler, M. Schmitz, S. Kloppner, M. Schedensack, and G. Jeserich et al. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo J Neurosci 28 50 2008 13609 13614 10.1523/JNEUROSCI.2765-08.2008
55. V.E. Miron, S.P. Zehntner, T. Kuhlmann, S.K. Ludwin, T. Owens, and T.E. Kennedy et al. Statin therapy inhibits remyelination in the central nervous system Am J Pathol 174 5 2009 1880 1890 10.2353/ajpath.2009.080947
56. A.S. Paintlia, M.K. Paintlia, A.K. Singh, and I. Singh Activation of PPAR-γ and PTEN cascade participates in lovastatin-mediated accelerated differentiation of oligodendrocytes progenitor cells Glia 58 14 2010 1669 1685 10.1002/glia.21039
57. A.S. Paintlia, M.K. Paintlia, A.K. Singh, and I. Singh Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR-α- dependent mechanism Glia 61 9 2013 1500 1517 10.1002/glia.22537
58. A.S. Paintlia, M.K. Paintlia, A.K. Singh, and I. Singh Synergistic activity of interleukin-17 and tumor necrosis factor-α enhance oxidative stress-mediated oligodendrocyte apoptosis J Neurochem 116 4 2011 508 521 10.1111/j.1471-4159.2010.07136.x
59. S. Hendrix, and R. Nitsch The role of T helper cells in neuroprotection and regeneration J Neuroimmunol 184 1-2 2007 100 112 10.1016/j.jneuroim.2006.11. 019
60. A.S. Paintlia, M.K. Paintlia, I. Singh, and A.K. Singh IL-4-induced peroxisome proliferator-activated receptor gamma activation in central nervous system (CNS) glial cells and protects oligodendrocyte progenitors under neuroinflammatory disease conditions: implication for CNS-demyelinating diseases J Immunol 176 7 2006 4285 4298
61. K. Pahan, F.G. Sheikh, A.M. Nambbodiri, and I. Singh Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages J Clin Invest 100 11 1997 2671 2679 10.1172/JCI119812
62. P.J. van der Most, A.M. Dolga, I.M. Nijholt, P.G. Luiten, and U.L. Eisel Statins: mechanisms of neuroprotection Prog Neurobiol 88 1 2009 64 75 10.1016/j.pneurobio.2009.02.002
63. J. Bosel, F. Gandor, C. Harms, M. Synowitz, U. Harms, and P.C. Djoufack et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurons J Neurochem 92 6 2005 1386 1398 10.1111/j.1471-4159.2004.02980.x
64. H. Wu, D. Lu, H. Jiang, Y. Xiong, C. Qu, and B. Li et al. Simvastatin-mediated up-regulation of VEGF and BDNF, activation of PI3K/Akt pathways, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury J Neurotrauma 25 2 2008 130 139 10.1089/neu.2007.0369
65. P. Marz, U. Otten, and A.R. Miserez Statins induce differentiation and cell death in neurons and astroglia Glia 55 1 2007 1 12 10.1002/glia.20422
66. J.G. Schulz, J. Bosel, M. Stoeckel, D. Megow, U. Dirnagl, and M. Endres HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis J Neurochem 89 1 2004 24 32 10.1046/j.1471-4159.2003.02305.x
67. Z. Xiang, and S.A. Reeves Simvastatin induces cell death in a mouse cerebellar slice culture (CSC) model of developmental myelination Exp Neurol 215 1 2009 41 47 10.1016/j.expneurol.2008.09.010
68. A. Sena, R. Pedrosa, and M. Graca Morais Therapeutic potential of lovastatin in multiple sclerosis J Neurol 250 6 2003 754 755 10.1007/s00415-003-1070-8
69. T. Vollmer, L. Key, V. Durkalski, W. Tyor, J. Corboy, and S. Markovic-Plese et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis Lancet 363 9421 2004 1607 1608
70. G. Birnbaum, B. Cree, I. Altafullah, M. Zinser, and A.T. Reder Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis Neurology 71 18 2008 1390 1395 10.1212/01.wnl.0000319698.40024.1c
71. J. Sellner, I. Greeve, O. Findling, C.P. Kamm, C. Minten, and B. Engelhardt et al. Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis Neurochem Int 53 1-2 2008 17 21 10.1016/j.neuint.2008.04.004
72. X. Feng, D. Han, K.K. Bharat, S.F. Beverly, T.B. Niewold, and A.T. Reder Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins Arch Neurol 69 10 2012 1303 1309 10.1001/archneurol.2012.465
73. P.S. Sorensen, J. Lycke, J.P. Erälinna, A. Edland, X. Wu, and J.L. Frederiksen for the SIMCOMBIN study investigators Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial Lancet Neurol 10 8 2011 691 701 10.1016/S1474-4422(11)70144-2
74. C.P. Kamm, M. El-Koussy, S. Humpert, O. Findling, F. von Bredow, and Y. Burren et al. Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled J Neurol 259 11 2012 2401 2413 10.1007/s00415-012-6513-7
75. R.A. Rudick, A. Pace, M.R. Rani, R. Hyde, M. Panzara, and S. Appachi et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a Neurology 72 23 2009 1989 1993 10.1212/WNL.0b013e3181a92b96
76. R.A. Rudick, W.H. Stuart, P.A. Calabresi, C. Confavreux, S.L. Galetta, and E.W. Radue for the SENTINEL Investigators Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 9 2006 911 923 10.1056/NEJMoa044396
77. F. Paul, S. Waiczies, J. Wuerfel, J. Bellmann-Strobl, J. Dörr, and H. Waiczies et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis PLoS ONE 3 4 2008 e1928 10.1371/journal.pone.0001928
78. R. Lanzillo, G. Orefice, M. Quarantelli, C. Rinaldi, A. Prinster, and G. Ventrella et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy Mult Scler 16 4 2010 450 454 10.1177/1352458509358909
79. M. Togha, S.A. Karvigh, M. Nabavi, N.B. Moghadam, M.H. Harirchian, and M.A. Sahraian et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial Mult Scler 16 7 2010 848 854 10.1177/1352458510369147
80. J. Wang, Y. Xiao, M. Luo, and H. Luo Statins for multiple sclerosis Cochrane Database Syst Rev 7 12 2011 CD008386 10.1002/14651858.CD008386.pub3
81. S. Bhardwaj, C.I. Coleman, and D.M. SoBieraj Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis Am J Health Syst Pharm 69 2012 1494 1499 10.2146/ajhp110675
82. O. Stüve, S. Youssef, M.S. Weber, S. Nessler, H.C. von Büdingen, and B. Hemmer et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity J Clin Invest 116 4 2006 1037 1044 10.1172/JCI25805
83. NCT00429442. Simvastatin as an add-on treatment to copaxone for the treatment of relapsing multiple sclerosis. http://clinicaltrials.gov/ct2/show/ study/NCT00429442 [accessed 19.12.13].